de Leeuw P W, van Es P N, Tchang P T, de Bos R, Birkenhäger W H
Department of Medicine, Zuiderziekenhuis, Rotterdam, The Netherlands.
J Hypertens Suppl. 1988 Dec;6(4):S416-7.
Previous experiments have shown that blockade of intrarenal alpha 2-adrenoceptors will cause a rise in renin secretion. Therefore, we designed the present study to explore whether this could be due to noradrenaline being released by a prejunctional mechanism and stimulating post-junctional beta 1-adrenoceptors. Two groups of patients in whom diagnostic renal angiography was indicated were studied before administration of contrast material. None of the patients had taken any antihypertensive medication in the 3 weeks preceding this investigation. In group I (n = 8) glucose was infused into the renal artery for 20 min; during the last 10 min yohimbine was also infused at a rate of 3 micrograms/kg per min. In group II (n = 8) the same protocol was carried out with the exception that, instead of glucose, we infused atenolol in a dose of 1 micrograms/kg per min. Blood samples for noradrenaline and renin were taken before infusions started, following 10 min of the glucose (or atenolol) and at the end of the yohimbine infusion. At the same time blood pressure and renal blood flow (133Xe-washout) were measured. The results show that yohimbine increased renin release by 310 +/- 60% in group I, but by only 80 +/- 45% in group II (P less than 0.01). However, noradrenaline 'release' was stimulated to the same degree in both groups (150 +/- 80 versus 138 +/- 75%; NS) During the experiments blood pressure and heart rate did not change. The data are consistent with the hypothesis that the effect of alpha 2-adrenoceptors on renin release is mediated by beta-adrenoceptors. Thus, the relevant alpha 2-receptor may be located prejunctionally.
以往的实验表明,阻断肾内α2 - 肾上腺素能受体可导致肾素分泌增加。因此,我们设计了本研究,以探讨这是否可能是由于去甲肾上腺素通过节前机制释放并刺激节后β1 - 肾上腺素能受体所致。在两组有诊断性肾血管造影指征的患者中,于注射造影剂前进行了研究。在本次研究前的3周内,所有患者均未服用任何抗高血压药物。第一组(n = 8)患者,肾动脉内输注葡萄糖20分钟;在最后10分钟,还以每分钟3微克/千克的速率输注育亨宾。第二组(n = 8)患者采用相同方案,只是输注的不是葡萄糖,而是剂量为每分钟1微克/千克的阿替洛尔。在开始输注前、葡萄糖(或阿替洛尔)输注10分钟后以及育亨宾输注结束时采集血样,检测去甲肾上腺素和肾素。同时测量血压和肾血流量(133Xe清除法)。结果显示,育亨宾使第一组肾素释放增加310±60%,但在第二组中仅增加80±45%(P<0.01)。然而,两组中去甲肾上腺素的“释放”受到同等程度的刺激(150±80%对138±75%;无显著性差异)。实验过程中血压和心率未发生变化。这些数据与α2 - 肾上腺素能受体对肾素释放的作用是由β - 肾上腺素能受体介导的这一假说相符。因此,相关的α2受体可能位于节前。